291 related articles for article (PubMed ID: 33980611)
1. EGR1 Addiction in Diffuse Large B-cell Lymphoma.
Kimpara S; Lu L; Hoang NM; Zhu F; Bates PD; Daenthanasanmak A; Zhang S; Yang DT; Kelm A; Liu Y; Li Y; Rosiejka A; Kondapelli A; Bebel S; Chen M; Waldmann TA; Capitini CM; Rui L
Mol Cancer Res; 2021 Aug; 19(8):1258-1269. PubMed ID: 33980611
[TBL] [Abstract][Full Text] [Related]
2. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
3. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
[TBL] [Abstract][Full Text] [Related]
4. Targetable genetic alterations of
Jain N; Hartert K; Tadros S; Fiskus W; Havranek O; Ma MCJ; Bouska A; Heavican T; Kumar D; Deng Q; Moore D; Pak C; Liu CL; Gentles AJ; Hartmann E; Kridel R; Smedby KE; Juliusson G; Rosenquist R; Gascoyne RD; Rosenwald A; Giancotti F; Neelapu SS; Westin J; Vose JM; Lunning MA; Greiner T; Rodig S; Iqbal J; Alizadeh AA; Davis RE; Bhalla K; Green MR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217338
[TBL] [Abstract][Full Text] [Related]
5. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
6. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
7. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
[TBL] [Abstract][Full Text] [Related]
8. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
10. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
11. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma.
Liu Y; Kimpara S; Hoang NM; Daenthanasanmak A; Li Y; Lu L; Ngo VN; Bates PD; Song L; Gao X; Bebel S; Chen M; Chen R; Zhang X; Selberg PE; Kenkre VP; Waldmann TA; Capitini CM; Rui L
Blood; 2023 Nov; 142(22):1879-1894. PubMed ID: 37738652
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
13. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
15. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
16. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.
Ricker E; Verma A; Marullo R; Gupta S; Ye C; Pannellini T; Manni M; Tam W; Inghirami G; Elemento O; Cerchietti L; Pernis AB
Sci Rep; 2020 Aug; 10(1):13094. PubMed ID: 32753663
[TBL] [Abstract][Full Text] [Related]
17. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
19. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth
Anastasiadou E; Seto AG; Beatty X; Hermreck M; Gilles ME; Stroopinsky D; Pinter-Brown LC; Pestano L; Marchese C; Avigan D; Trivedi P; Escolar DM; Jackson AL; Slack FJ
Clin Cancer Res; 2021 Feb; 27(4):1139-1149. PubMed ID: 33208342
[TBL] [Abstract][Full Text] [Related]
20. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]